OBJECTIVES: Besides the well-known role of the angiotensin system in blood pressure control, an interaction of angiotensin and pain perception has been suggested. This study sought to investigate whether an angiotensin converting enzyme inhibitor, which facilitates bradykinins, algesic peptides, and/or an AT1 receptor antagonist may modify hypertension-related hypoalgesia in humans. The study was approved by the ethical committee of our Department. METHODS: A total of 22 hypertensive patients were submitted to dental pulp stimulation to obtain the dental pain threshold and tolerance, and to 24 h blood pressure monitoring together with a control group of 55 normotensives. Then the hypertensives were randomized to enalapril or losartan treatment and were re-evaluated (dental pain perception and ambulatory monitoring) after 8 weeks of the first treatment and after an additional 8 weeks of the second treatment. RESULTS: Untreated hypertensives showed a reduced perception to painful stimuli when compared with normotensives. A significant reduction of both pain threshold and tolerance was observed during the anti-hypertensive treatments (Friedman test: P = 0.007 and P = 0.006, respectively). Pain sensitivity was similar during the two treatments and it did not differ from pain sensitivity values of normotensive controls. ANCOVAs were computed to evaluate the relationship between anti-hypertensive agents and pain sensitivity, after controlling for blood pressure. A 24 h mean pressure served as covariate, removing any effect of blood pressure; a significant difference was observed entering both pain threshold and tolerance as dependent variables (F = 5.28, P = 0.0076; F = 8.16, P = 0.0007, respectively). CONCLUSIONS: Both the angiotensin converting enzyme inhibitor enalapril and the AT1 receptor blocking agent losartan acted similarly on pain threshold and tolerance, pain sensitivity being increased during the two anti-hypertensive treatments. The blood pressure reduction during drug assumption could not account for the pain sensitivity changes observed. The latter may be due to a specific pharmacodynamic mechanism mediated through angiotensin II AT1 receptors.
RCT Entities:
OBJECTIVES: Besides the well-known role of the angiotensin system in blood pressure control, an interaction of angiotensin and pain perception has been suggested. This study sought to investigate whether an angiotensin converting enzyme inhibitor, which facilitates bradykinins, algesic peptides, and/or an AT1 receptor antagonist may modify hypertension-related hypoalgesia in humans. The study was approved by the ethical committee of our Department. METHODS: A total of 22 hypertensivepatients were submitted to dental pulp stimulation to obtain the dental pain threshold and tolerance, and to 24 h blood pressure monitoring together with a control group of 55 normotensives. Then the hypertensives were randomized to enalapril or losartan treatment and were re-evaluated (dental pain perception and ambulatory monitoring) after 8 weeks of the first treatment and after an additional 8 weeks of the second treatment. RESULTS: Untreated hypertensives showed a reduced perception to painful stimuli when compared with normotensives. A significant reduction of both pain threshold and tolerance was observed during the anti-hypertensive treatments (Friedman test: P = 0.007 and P = 0.006, respectively). Pain sensitivity was similar during the two treatments and it did not differ from pain sensitivity values of normotensive controls. ANCOVAs were computed to evaluate the relationship between anti-hypertensive agents and pain sensitivity, after controlling for blood pressure. A 24 h mean pressure served as covariate, removing any effect of blood pressure; a significant difference was observed entering both pain threshold and tolerance as dependent variables (F = 5.28, P = 0.0076; F = 8.16, P = 0.0007, respectively). CONCLUSIONS: Both the angiotensin converting enzyme inhibitor enalapril and the AT1 receptor blocking agent losartan acted similarly on pain threshold and tolerance, pain sensitivity being increased during the two anti-hypertensive treatments. The blood pressure reduction during drug assumption could not account for the pain sensitivity changes observed. The latter may be due to a specific pharmacodynamic mechanism mediated through angiotensin II AT1 receptors.
Authors: James A McCubbin; Marcellus M Merritt; John J Sollers; Michele K Evans; Alan B Zonderman; Richard D Lane; Julian F Thayer Journal: Psychosom Med Date: 2011-10-31 Impact factor: 4.312
Authors: Louisa Edwards; Christopher Ring; Christopher R France; Mustafa al'Absi; David McIntyre; Douglas Carroll; Una Martin Journal: Biol Psychol Date: 2007-06-30 Impact factor: 3.251
Authors: Christine Miaskowski; Bruce Cooper; Steven M Paul; Claudia West; Dale Langford; Jon D Levine; Gary Abrams; Deborah Hamolsky; Laura Dunn; Marylin Dodd; John Neuhaus; Christina Baggott; Anand Dhruva; Brian Schmidt; Janine Cataldo; John Merriman; Bradley E Aouizerat Journal: J Pain Date: 2012-12 Impact factor: 5.820
Authors: Shad B Smith; Ellen Mir; Eric Bair; Gary D Slade; Ronald Dubner; Roger B Fillingim; Joel D Greenspan; Richard Ohrbach; Charles Knott; Bruce Weir; William Maixner; Luda Diatchenko Journal: J Pain Date: 2013-12 Impact factor: 5.820
Authors: Frances M K Williams; Serena Scollen; Dandan Cao; Yasin Memari; Craig L Hyde; Baohong Zhang; Benjamin Sidders; Daniel Ziemek; Yujian Shi; Juliette Harris; Ian Harrow; Brian Dougherty; Anders Malarstig; Robert McEwen; Joel C Stephens; Ketan Patel; Cristina Menni; So-Youn Shin; Dylan Hodgkiss; Gabriela Surdulescu; Wen He; Xin Jin; Stephen B McMahon; Nicole Soranzo; Sally John; Jun Wang; Tim D Spector Journal: PLoS Genet Date: 2012-12-20 Impact factor: 5.917
Authors: Miklós Palkovits; Katarína Šebeková; Kristina Simon Klenovics; Anton Kebis; Gholamreza Fazeli; Udo Bahner; August Heidland Journal: PLoS One Date: 2013-06-20 Impact factor: 3.240